P3HR-1 and Ramos cells induced with sodium butyrate and 12-O-tetradecanoylphorbol 13-acetate were used in the protein immure,blot technique to identify EpsteinBarr virus (EBV)-specific antibodies present in ser~ from clinically normal individuals and patients with systemic lupus erythematosus (SI,E), rheumatoid arthritis (RA) and infectious mononucleosis (IM). Sixteen EBV-sp,'cific polypeptides were detected ranging in tool. wt. from 22000 (22K) to 140K. Many of the sera contained antibodies to different subsets of these antigens, and a high pJ oportion expressed autoantibodies which reacted with cellular components from an EB V genome-negative cell line. About 50% of the sera from each category reacted with the 44K to 48K and 36K and 38K early antigen (EA) components. A high proportion of 1he SLE sera (64~) were found to contain anti-EA antibodies, suggesting an associati on between EBV and SLE. Almost all of the EBV-seropositive sera examined contai ned antibodies against a 22K late antigen, but none of the sera from IM patients r~ acted with this polypeptide.
Infection of human B-lymphocytes by Epstein-Barr, irus (EBV) results in the induction of a large number of EBV-associated antigen complexes. In non-permissive infections, a number of EBV-induced antigens have been described, including EBNA1 and EBNA2 (Reedman & Klein, 1973; Hennessy & Kieff, 1983; ScuUey et al., 1~.'84) . Virus-producing cell lines express additional antigen complexes which have been termed membrane antigens (MA), viral capsid antigens (VCA) and early antigens (EA) (Pearson, 1980~ . Healthy EBV-seropositive individuals usually have antibodies against EBNA1, MA and VC~ ~. In addition, antibodies against EBV EA often can be found in the sera of patients with vario~ is diseases, such as Burkitt's lymphoma (BL), nasopharyngeal carcinoma (NPC), systemic lu ~us erythematosus (SLE), rheumatoid arthritis (RA) and infectious mononucleosis (IM). Because of the nature of these diseases, a major problem in the detection of antibodies to tlte EBV antigens is the presence of autoantibodies in the sera of many patients (Gilliland & i dannik, 1980; Hardin & Mimori, 1985 ; Sutton et at., 1974) . However, this problem can be ov ",rcome by the use of immunoblotting, employing extracts of both EBV-positive and EBV-ne ,ative cell lines.
P3HR-1 and Ramos cell lines were grown in RPMI 1640 medium supplemented with 10% foetal calf serum at 37 °C under 5% CO2. Cells at a der sity of 106 per ml were induced with 5 mM-sodium butyrate and 20 ng/ml 12-O-tetradecan~ytphorbol 13-acetate (TPA) (Baker Chemical, Philipsburg, N.J., U.S.A. and Sigma, respectively) for 3 days. SDS extracts were prepared from these two lines and layered across the tot of 10% polyacrylamide-SDS slab gels. Proteins were separated by electrophoresis (Laemmli, 1970) , then electrophoretically transferred to nitrocellulose papers (Burnette, 1981) , which were cut into strips and incubated with individual samples of serum. When sera collected I rom clinically normal individuals were screened, each of the 16 EBV-seropositive sera reacted with two polypeptides, the 72000 mol. wt. (72K) EBNA1 antigen (Sculley et al., 1984) and th,: 22K late viral antigen (Sculley et al., 1985) in P3HR-1 cells, but not in Ramos cells ( ANA  RA17  10  IMI  IM2  IM3  IM4  IM5  IM6  1M7  IM8  IM9  IM10  IMI1  IMI2  IMI3  IMI4  IMI5 * Titres measured according to Reedman & Klein (1973) . "t" Titres measured according to Klein & Dombos (1973) . :~ Titres measured according to Henle & Henle (1966) specific polypeptides at 50K and 42K (Table 2) . None of these antigens was detected with four EBV-seronegative sera. There was little or no reaction with the Ramos cell line in contrast to the results obtained with SLE sera. Most of the sera from SLE patients were found to contain autoantibodies by immunofluorescence (Table 1) and this was also evident in the immunoblots on Ramos cells (Fig. 1 b) . Incubation of the sera with extracts of the P3HR-1 cell line also detected these cellular components, as well as a number of additional EBV-specific polypeptides (Fig. 1 a) . The most prominent EA polypeptides detected by immunoblotting are the 44K to 48K EA-D complex and the 36K and 38K antigens (Sculley et al., 1985) . Lanes 17 and 18 represent an RA and an NPC serum respectively which were anti-EA-positive by immunofluorescence and were known to react with the 44K to 48K and/or the 36K and 38K polypeptides in immunoblots (Sculley et al., 1985) and were included as reference sera. The results demonstrated that nine of the 14 sera from SLE patients (64~) reacted with the 36K and 38K proteins, and 50~ detected the 44K to 48K EA-D antigen. The high percentage of SLE sera containing anti-EA antibodies suggests an association between the disease and EBV. A preliminary study, where samples of sera were taken from the same patients at different stages of the disease, indicated that anti-EA antibodies may persist for an extended length of time (lanes 3 and 19 represent serum taken from patient SLE1, with an 8 month interval; lanes 5 and 20 were from patient SLE3, with a 22 month interval). Whether this is brought about by treatment of SLE patients (i.e. activation of the EBV genome by various drugs) or by the disease itself requires further study. Unlike the SLE sera, which were selected randomly, the sera from RA patients were tested by immunoblotting only if they were anti-EA-positive by immunofluorescence, with three autoantibody-positive sera being included. All of the RA patients included in this study were diagnosed through the Rheumatology Clinic at the Princess Alexandra Hospital, Brisbane and sera were obtained from patients with either classical or definite RA (American Rheumatism Association criteria). Even though these sera were anti-EA-positive by immunofluorescence, only four of the 17 sera reacted with the 44K to 48K EA-D antigen, and a further eight sera reacted with the 36K and 38K antigens (predominantly the 36K component) (results not shown, but summarized in Table 2 ). Two samples of sera which did not react with either the 44K to 48K or 36K to 38K antigens were autoantibody-positive by immunofluorescence and were therefore presumed to be anti-EA-negative. The failure of the remaining three anti-EA-positive sera to react with known EA components in the immunoblots indicates that not all the EA polypeptides, as defined by immunofluorescence, were detected using immunoblotfing. All of the sera reacted with EBNA1 despite the fact that three of the sera had titres of < 10 in anti-EBNA immunofluorescence tests (Table 1) , and all but one of the sera detected the 22K component. Once again, the immunoblot with Ramos cells indicated the presence of autoantibodies, with reaction mostly occurring with a polypeptide around 32K (results not shown). Almost 6 0~ of the R A sera detected this 32K protein, while none of the other groups studied reacted with the antigen. This apparently RA-specific autoantibody m a y have some importance as a diagnostic tool and bears further study. Sera from suspected I M patients were received from the Queensland University Health Services and a positive diagnosis confirmed by immunofluorescence tests for IgM antibodies to EBV. W i t h these sera, a variety of non-specific proteins were detected in the i m m u n o b l o t using Ramos cell extracts (Fig. 2b) . Only 10 of the I M sera tested ( 6 6~) were found to have positive a n t i -E A -D + R titres by immunofluorescence. O f these sera, seven reacted with either, or both, the 44K to 48K and 36K and 38K polypeptides in P3HR-1 cells. U n l i k e the other diseases studied, only 13 ~ (two out of 15 patients) reacted with E B N A 1. Some of the sera, however, did react with a cellular c o m p o n e n t at 72K in both the P3HR-1 and R a m o s cell extracts. The most interesting feature of the sera from IM patients was their inability to detect the 22K antigen, despite the fact that all the sera were anti-VCA-positive by immunofluorescence. This 22K protein has previously been shown to be a late viral product (Sculley et al., 1985) and may be either a VCA or MA component. Because anti-EA-negative, anti-VCA-positive sera react with this antigen (Table 2) , and because it is not present in virus non-producing cell lines (Sculley et al., 1984) , it is likely to be a component of the viral particle. It is therefore surprising that sera from patients in the acute phase of IM fail to react with the antigen. The method employed in the immunoblots utilizes the binding of radioiodinated Protein A to antibody-antigen complexes and would not detect IgM antibodies. The possibility that only IgM antibodies, in IM patients, are directed against the 22K antigen was investigated by both employing anti-human IgM serum raised in rabbits, as a bridge in the immunoblots, and by using peroxidase-labelled antihuman Ig, but still no reaction with the 22K antigen was detected (results not shown). The presence of anti-22K antibodies in normal sera indicates that some time after the acute phase of IM, individuals eventually develop these antibodies and then appear to maintain them for life. Further study will be required to determine the length of time after onset of IM that anti-22K antibodies appear and whether they may serve some protective function.
